On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval was based on data from the global, randomized Phase 3 RASolute 302 clinical trial comparing RASONQUE to investigator’s choice of cytotoxic chemotherapy. Once-daily oral tablets are now available in the United States, with a wholesale acquisition cost of $39,800 for a 30-day supply based on the recommended daily dose. Revolution Medicines operates as a biopharmaceutical company focused on developing targeted therapies for cancer.
